Technical Analysis for BBLG - Bone Biologics Corp
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 1.63% | |
| Wide Bands | Range Expansion | 1.63% | |
| MACD Bullish Signal Line Cross | Bullish | -0.79% | |
| Narrow Range Bar | Range Contraction | -0.79% | |
| Inside Day | Range Contraction | -0.79% | |
| Wide Bands | Range Expansion | -0.79% | |
| Wide Bands | Range Expansion | -5.30% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 13 hours ago |
| 60 Minute Opening Range Breakout | about 16 hours ago |
| Rose Above 10 DMA | about 16 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Bone Biologics Corp Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Biopharmaceutical Clinical Medicine Surgery Neurosurgery Platform Technology Orthopedic Surgery Sports Medicine Surgical Specialties Spinal Fusion Degenerative Disc Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.56 |
| 52 Week Low | 0.8 |
| Average Volume | 3,849,706 |
| 200-Day Moving Average | 1.80 |
| 50-Day Moving Average | 1.66 |
| 20-Day Moving Average | 1.31 |
| 10-Day Moving Average | 1.24 |
| Average True Range | 0.16 |
| RSI (14) | 42.86 |
| ADX | 12.09 |
| +DI | 22.98 |
| -DI | 21.50 |
| Chandelier Exit (Long, 3 ATRs) | 1.32 |
| Chandelier Exit (Short, 3 ATRs) | 1.61 |
| Upper Bollinger Bands | 1.54 |
| Lower Bollinger Band | 1.08 |
| Percent B (%b) | 0.37 |
| BandWidth | 35.27 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.12 |
| MACD Histogram | 0.0095 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.36 | ||||
| Resistance 3 (R3) | 1.36 | 1.32 | 1.34 | ||
| Resistance 2 (R2) | 1.32 | 1.30 | 1.32 | 1.33 | |
| Resistance 1 (R1) | 1.29 | 1.28 | 1.31 | 1.29 | 1.33 |
| Pivot Point | 1.25 | 1.25 | 1.26 | 1.25 | 1.25 |
| Support 1 (S1) | 1.22 | 1.23 | 1.24 | 1.22 | 1.17 |
| Support 2 (S2) | 1.18 | 1.21 | 1.18 | 1.17 | |
| Support 3 (S3) | 1.15 | 1.18 | 1.16 | ||
| Support 4 (S4) | 1.15 |
